Q-omics provides the consensus-scored RPS29P17 profile across patient tissues and cancer cell-line models. RPS29P17 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RPS29P17 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RPS29P17 RNA expression shows 11,759 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, COAD, and TGCT as cancer lineages where RPS29P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29P17 survival associations across molecular data types. RPS29P17 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29P17 RNA expression–survival associations across cancer types. High RPS29P17 expression shows unfavorable associations in MESO and KIRP, but favorable associations in UCS, READ, BLCA and THCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for RPS29P17 RNA expression.
This table summarizes RPS29P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS29P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29P17 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, HNSC, PRAD and BLCA. The COAD box plot shows higher RPS29P17 RNA expression in tumor versus normal tissue (log2 FC = +0.957, t-test p < 0.001).
This table shows molecular features associated with RPS29P17 in patient tissues and cancer cell lines. In patient samples, RPS29P17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
